Compile Data Set for Download or QSAR
Report error Found 84 Enz. Inhib. hit(s) with all data for entry = 11342
TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608724(US11697650, Compound 1 | US11697650, Example 35)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608706(US11697650, Compound 5 | US11697650, Example 15)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608720(US11697650, Compound 2 | US11697650, Example 30)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608731(US11697650, Compound 48 | US11697650, Example 42)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608704(US11697650, Compound 3 | US11697650, Example 13)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608719(US11697650, Compound 7 | US11697650, Example 28)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608721(US11697650, Compound 6 | US11697650, Example 31)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608702(US11697650, Compound 33 | US11697650, Example 11)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608700(US11697650, Compound 31 | US11697650, Example 9 | ...)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608408(US11697650, Compound 4 | US11697650, Example 2 | N...)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608725(US11697650, Compound 8 | US11697650, Example 37)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608716(US11697650, Compound 9 | US11697650, Example 25)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608413(US11697650, Compound 11 | US11697650, Example 5 | ...)
Affinity DataIC50: 5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608715(US11697650, Compound 39 | US11697650, Example 24)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608727(US11697650, Compound 43 | US11697650, Example 41)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608410(US11697650, Compound 14 | US11697650, Example 3 | ...)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608703(US11697650, Compound 19 | US11697650, Example 12)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608411(US11697650, Compound 20 | US11697650, Example 4 | ...)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608723(US11697650, Compound 13 | US11697650, Example 33)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608711(US11697650, Compound 37 | US11697650, Example 20)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608726(US11697650, Compound 12 | US11697650, Example 38)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608406(US11697650, Compound 15 | US11697650, Example 1 | ...)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608722(US11697650, Compound 10 | US11697650, Example 32)
Affinity DataIC50: 7.5nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608712(US11697650, Compound 38 | US11697650, Example 21)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608710(US11697650, Compound 18 | US11697650, Example 19 |...)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608729(US11697650, Compound 46 | US11697650, Example 42)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608717(US11697650, Compound 23 | US11697650, Example 26)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608728(US11697650, Compound 45 | US11697650, Example 42)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608709(US11697650, Compound 35 | US11697650, Example 18)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608708(US11697650, Compound 24 | US11697650, Example 17)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608707(US11697650, Compound 16 | US11697650, Example 16)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608701(US11697650, Compound 32 | US11697650, Example 10)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608698(US11697650, Compound 17 | US11697650, Example 7 | ...)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608697(US11697650, Compound 21 | US11697650, Example 6 | ...)
Affinity DataIC50: 30nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608732(US11697650, Compound 49 | US11697650, Example 42)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608705(US11697650, Compound 34 | US11697650, Example 14)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608730(US11697650, Compound 47 | US11697650, Example 42)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608733(US11697650, Compound 50 | US11697650, Example 42)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608699(US11697650, Compound 30 | US11697650, Example 8 | ...)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608713(US11697650, Compound 26 | US11697650, Example 22)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608714(US11697650, Compound 22 | US11697650, Example 23)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608718(US11697650, Compound 27 | US11697650, Example 27)
Affinity DataIC50: 50nMAssay Description:The following assay concentrations and times were used: 3 ng BCL-2, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled acce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608724(US11697650, Compound 1 | US11697650, Example 35)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608723(US11697650, Compound 13 | US11697650, Example 33)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608725(US11697650, Compound 8 | US11697650, Example 37)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608726(US11697650, Compound 12 | US11697650, Example 38)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608719(US11697650, Compound 7 | US11697650, Example 28)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608406(US11697650, Compound 15 | US11697650, Example 1 | ...)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608408(US11697650, Compound 4 | US11697650, Example 2 | N...)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

TargetBcl-2-like protein 1(Human)
Eil Therapeutics

US Patent
LigandPNGBDBM608710(US11697650, Compound 18 | US11697650, Example 19 |...)
Affinity DataIC50: 2.00E+3nMAssay Description:The following assay concentrations and times were used: 10.5 ng BCL-XL, 5 μl of 1:100 anti-His Tb-labeled donor, 5 μl of 1:100 Dye-labeled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/11/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 84 total ) | Next | Last >>
Jump to: